Lab-grown food products of animal cell origin, now becoming popularly coined as, ‘Cellular Agriculture’ is a revolutionary breakthrough technology that has the potential to penetrate the lives of every American or citizen of the world. It is important to recognize that the impetus for developing this technology is fueled by environmental concerns with climate change, rising geopolitical instability, and population growth projections, where farm-grown food has now become a growing national security issue. Notwithstanding its potential, in addition to the necessary technological innovation and economic scalability, the market success of cellular agriculture will depend greatly on regulatory oversight by multiple government agencies without which it can cause undue harm to individuals, populations, and the environment. Thus, it is critical for those appropriate United States governing bodies to ensure that the technology being developed is both safe and of an acceptable quality for human consumption and has no adverse environmental impact. As such, animal foods, derived from farms, previously regulated almost exclusively by the United States Department of Agriculture (USDA) are now being regulated under a joint formal agreement between the US Food and Drug Administration (US FDA) and the USDA if derived from the lab, i.e., lab-grown animal foods. The main reason for joint oversight between the FDA and the USDA is that the FDA has developed the in-house expertise to oversee primary cell harvesting and cell storage, as well as, cell growth and differentiation for the development of 3D-engineered tissues intended for tissue and organ replacement for the emerging field of regenerative medicine. As such, the FDA has been given the authority to oversee the ‘front end’ of lab-grown food processes which relies on the very same processes utilized in engineered human tissues to produce food-grade engineered tissues. Oversight then transitions to the USDA-FSIS (Food Safety and Inspection Service) during the harvesting stage of the cell culture process. The USDA-FSIS then oversees the further production and labeling of these products. Included in the agreement is the understanding that both bodies are responsible for communicating necessary information to each other and collaboratively developing new regulatory actions as needed. However, there currently lacks clarity on some topics regarding certain legal, ethical, and scientific issues. Lab-grown meat products require more extensive regulation than farm-grown animal food products to ensure that they are safe and nutritious for consumption. To do this, CFSAN can create new classes of lab-grown foods, such as ‘lab-grown USDA foods,’ ‘lab-grown non-USDA foods,’ ‘lab-grown extinct foods,’ ‘lab-grown human food tissues,’ and ‘medically activated lab-grown foods.’

Traumatic brain injury (TBI) is defined as an injury to the head that disrupts normal brain function. TBI has been described as a disease process that can lead to an increased risk for developing chronic neurodegenerative diseases, like frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). A pathological hallmark of FTLD and a hallmark of ALS is the nuclear mislocalization of TAR DNA Binding Protein 43 (TDP-43). This project aims to explore neurodegenerative effects of TBI on cortical lesion area using immunohistochemical markers of TDP-43 proteinopathies. We analyzed the total percent of NEUN positive cells displaying TDP-43 nuclear mislocalization. We found that the percent of NEUN positive cells displaying TDP-43 nuclear mislocalization was significantly higher in cortical tissue following TBI when compared to the age-matched control brains. The cortical lesion area was analyzed for each injured brain sample, with respect to days post-injury (DPI), and it was found that there were no statistically significant differences between cortical lesion areas across time points. The percent of NEUN positive cells displaying TDP-43 nuclear mislocalization was analyzed for each cortical tissue sample, with respect to cortical lesion area, and it was found that there were no statistically significant differences between the percent of NEUN positive cells displaying TDP-43 nuclear mislocalization, with respect to cortical lesion area. In conclusion, we found no correlation between the percent of cortical NEUN positive cells displaying TDP-43 nuclear mislocalization with respect to the size of the cortical lesion area.

Regenerative medicine utilizes living cells as therapeutics to replace or repair damaged or diseased tissue, but the manufacturing processes to produce cell-based tissue products require customized biounit operations that do not currently exist as conventional biochemical and biopharma manufacturing processes. Living cells are constantly changing and reacting to their environment, which in the case of cells isolated from their hosts, are utilized as living bioreactor components that, by themselves, are manipulated to biomanufacturer selected tissue products. Therefore, specialized technology is required to assure that cellular products produce the phenotypical tissue characteristics that the final product is designated to have, while also maintaining sterility of the culture. Because of this, FDA guidelines encourage the use of Process Analytical Technology (PAT – see Ref ) to be integrated into manufacturing systems of biologics to ensure quality and safety. To address the need for evaluation of sensor technologies for potential use in PAT, a literature review of both existing sensing technologies and biomarkers was conducted. After a thorough assessment of the sensor technologies that were most applicable to biomanufacturing, spectrophotometry was selected to monitor the metabolic components glucose and lactate of living cells in culture in real time. Initially, spectrophotometric measurements were taken of mock solutions of glucose and lactate solutions at concentrations relevant to human cell culture and physiology. With that data, a mathematical model was developed to predict a solution’s glucose and lactate concentration. This model was then integrated into a Matlab program that was used to continuously monitor and estimate solutions of glucose and lactate concentrations in real time. After testing the accuracy of this program in different solutions, it was determined that calibration curves and models must be made for each media type and estimates of glucose and lactate were found accurate only at higher concentrations. This program was successfully utilized to monitor in real time glucose and lactate production and consumption trends of Mesenchymal Stem Cells (MSCs) in culture, demonstrating proof-of-concept of the proposed bioprocess monitoring schema.